WITHDRAWN: Genetic complexity alters drug susceptibility of asexual and gametocyte stages of P. falciparum to antimalarial candidates
Preprint
Abstract
Malaria elimination requires interventions able to target both the asexual blood stage (ABS) parasites and transmissible gametocyte stages of Plasmodium falciparum. Lead antimalarial candidates are evaluated against clinical isolates to address key concerns regarding efficacy and confirm that the current, circulating parasites from endemic regions lacks resistance against these candidates. Whilst this has largely been performed on ABS parasites, limited data is available on the transmission-blocking efficacy of compounds with multistage activity. Here, we evaluated the efficacy of lead antimalarial candidates against both ABS parasites and late-stage gametocytes side-by-side, against clinical P. falciparum isolates from southern Africa. We additionally correlated drug efficacy to the genetic diversity of the clinical isolates as determined with a panel of well-characterized, genome spanning microsatellite (MS) markers. Our data indicate varying sensitivities of the isolates to key antimalarial candidates, both for ABS parasites and gametocyte stages. While ABS parasites were efficiently killed, irrespective of genetic complexity, antimalarial candidates lost some gametocytocidal efficacy when the gametocytes originated from genetically complex, multiple clone infections. This suggests a fitness benefit to multiclone isolates to sustain transmission and reduce drug susceptibility. In conclusion, this is the first study to investigate the efficacy of antimalarial candidates on both ABS parasites and gametocytes from P. falciparum clinical isolates where the influence of parasite genetic complexity is highlighted, ultimately aiding the malaria elimination agenda.Keywords
This publication has 72 references indexed in Scilit:
- Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markersMalaria Journal, 2013
- Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetProceedings of the National Academy of Sciences, 2012
- Population genetic structure of Plasmodium falciparum across a region of diverse endemicity in West AfricaMalaria Journal, 2012
- The Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium falciparum Transmission to Anopheles Mosquito VectorAntimicrobial Agents and Chemotherapy, 2012
- Application of genomics to field investigations of malaria by the international centers of excellence for malaria researchActa Tropica, 2011
- Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and EliminationClinical Microbiology Reviews, 2011
- Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malariaProceedings of the National Academy of Sciences, 2011
- Selection of Known Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina FasoAntimicrobial Agents and Chemotherapy, 2010
- Transmission stage investment of malaria parasites in response to in-host competitionProceedings Of The Royal Society B-Biological Sciences, 2007
- Common Origin and Fixation of Plasmodium falciparum dhfr and dhps Mutations Associated with Sulfadoxine-Pyrimethamine Resistance in a Low-Transmission Area in South AmericaAntimicrobial Agents and Chemotherapy, 2007